A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53WILD-TYPE, ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA

Status: Recruiting

Eligibility Criteria

Sex: Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- confirmed Endometrial cancer including: endometrioid, serous, undifferentiated, and carcinosarcoma - Stage IV disease at diagnosis or first relapse - may be unable to do physically strenuous activity but walk and carry out work of a light or sedentary nature, e.g., light house work, office work - see link to clinicaltrials.gov for complete Inclusion criteria

Exclusion Criteria:

- gastrointestinal disease that could interfere with the absorption of selinexor (e.g., bowel obstruction, inability to swallow tablets, malabsorption syndrome, unresolved nausea, vomiting, diarrhea) - serious psychiatric or medical condition that could interfere with participation - another cancer in the past 3 years - women who are pregnant or breastfeeding - see link to clinicaltrials.gov for complete Exclusion criteria

Conditions & Interventions

Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), Endometrial Cancer

More Information

Description: The purpose of this research study is to further evaluate the safety and effectiveness of selinexor for maintenance in patients with TP53 wild-type endometrial cancer.
Study Contact: Sydney Hansen - hans6041@umn.edu
Principal Investigator: Britt Erickson
IRB Number: STUDY00025314